Schroders Stock Earnings Reports

Key points for investors:

- M&A: Schroders has received an all-cash offer from Nuveen/TIAA (GBP 5.90 cash + up to GBP 0.22 in permitted dividends = GBP 6.12), which the Schroders Board has unanimously recommended. The offer implies ~17x 2025 fully diluted adjusted operating EPS and a premium of 34% to the prior close (47% vs 3-month VWAP, 61% vs 12-month VWAP). The Board views the combination as strategically complementary (public + private markets scale, stronger U.S. distribution) and expects the deal to close in Q4 (subject to regulatory approvals). Nuveen has given commitments on retaining the Schroders brand, investment & client teams globally, and keeping London as the non-U.S. HQ.

- 2025 results: strong operational year and first year of a 3-year transformation program. AUM reached a record GBP 824bn (up 6%), gross inflows GBP 142bn, net inflows GBP 11.2bn. Operating profit rose ~25% and adjusted operating EPS increased 29%. Over 70% of assets outperformed over 1/3/5 years.

- Flows and regional dynamics: Public Markets net new business improved to GBP 3.7bn (from negative prior year), with strong intermediary and Asia/EMEA momentum (particularly Q4). Schroders Capital fundraising was GBP 10.9bn (flat year-on-year) but conversion/deployment of dry powder needs acceleration. Wealth Management saw revenue and margin improvement but weaker net new business overall; UK private wealth performed well. Joint ventures had an outflow (~GBP 5bn) driven by the Chinese JV fund manager.

- Transformation & costs: Management delivered GBP 75m of in-year savings (net of reinvestment) and ~£100m of annualized net savings to date, with headcount down ~10% and supplier base reduced. Target is GBP 150m net annualized savings by 2027 and a cost-to-income ratio below 70% (expecting mid-70s -> toward 70% in 2026). Adjusted operating expenses were broadly flat; transformation reinvestment continues.

- Capital & balance sheet: Estimated capital surplus of GBP 865m after an estimated GBP 250m impact from Basel 3.1. Management will continue to follow its capital allocation framework.

- Investor implications & risks: The deal offers immediate certain cash value and strategic acceleration (management says it accelerates growth plans by ~a decade). Transaction is subject to regulatory approvals and customary conditions. Nuveen/TIAA commitments around brand, teams, and UK presence mitigate some execution and retention risk but integration and regulatory execution remain key.